-
公开(公告)号：US20230134307A1
公开(公告)日：2023-05-04
申请号：US18087302
申请日：2022-12-22
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , A61P25/18 , C07D401/06
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20190300536A1
公开(公告)日：2019-10-03
申请号：US16366710
申请日：2019-03-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC: C07D487/04 , C07D471/04 , A61K9/20 , A61K9/48
Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
公开(公告)号：US20160176872A1
公开(公告)日：2016-06-23
申请号：US15055108
申请日：2016-02-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi YAMAMOTO , Junya SHIRAI , Tsuneo ODA , Mitsunori KONO , Atsuko OCHIDA , Takashi IMADA , Hidekazu TOKUHARA , Yoshihide TOMATA , Naoki ISHII , Michiko TAWADA , Yoshiyuki FUKASE , Tomoya YUKAWA , Shoji FUKUMOTO
IPC: C07D471/04
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
Abstract translation: 本发明提供具有RORγt抑制作用的杂环化合物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义。 或其盐。
-
公开(公告)号：US20170253591A1
公开(公告)日：2017-09-07
申请号：US15510225
申请日：2015-09-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Satoshi YAMAMOTO , Junya SHIRAI , Tsuneo ODA , Takashi IMADA , Mitsunori KONO , Ayumu SATO , Yoshihide TOMATA , Atsuko OCHIDA , Naoki ISHII , Yusuke SASAKI , Yoshiyuki FUKASE , Tomoya YUKAWA , Shoji FUKUMOTO
IPC: C07D471/04 , C07D413/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D239/96 , C07D409/14 , C07D403/12 , C07D401/12 , C07D417/14 , C07D401/14 , C07D413/14
CPC classification number: C07D471/04 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P1/00 , A61P11/00 , C07D239/96 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
-
公开(公告)号：US20160002169A1
公开(公告)日：2016-01-07
申请号：US14755439
申请日：2015-06-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi YAMAMOTO , Junya SHIRAI , Tsuneo ODA , Mitsunori KONO , Atsuko OCHIDA , Takashi IMADA , Hidekazu TOKUHARA , Yoshihide TOMATA , Naoki ISHII , Michiko TAWADA , Yoshiyuki FUKASE , Tomoya YUKAWA , Shoji FUKUMOTO
IPC: C07D217/26 , C07D491/056 , C07D491/048 , C07F7/08 , C07D471/04
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
-
Patent Agency Ranking
公开(公告)号：US20230150934A1
公开(公告)日：2023-05-18
申请号：US18087233
申请日：2022-12-22
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , A61P25/18 , C07D401/06
CPC classification number: C07D207/263 , A61P25/18 , C07D401/06
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20230002318A1
公开(公告)日：2023-01-05
申请号：US17755907
申请日：2020-11-12
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , C07D401/06 , A61P25/18
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20210332053A1
公开(公告)日：2021-10-28
申请号：US17201878
申请日：2021-03-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC: C07D487/04 , A61K9/20 , A61K9/48 , C07D471/04 , A61P25/00
Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
9.发明申请公开(公告)号：US20170144973A1
公开(公告)日：2017-05-25
申请号：US15321609
申请日：2015-06-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi YAMAMOTO , Junya SHIRAI , Tsuneo ODA , Mitsunori KONO , Atsuko OCHIDA , Takashi IMADA , Hidekazu TOKUHARA , Yoshihide TOMATA , Naoki ISHII , Michiko TAWADA , Yoshiyuki FUKASE , Tomoya YUKAWA , Shoji FUKUMOTO
IPC: C07D217/26 , C07D491/056 , C07D491/048 , C07F7/08 , C07D471/04
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号：US20160176873A1
公开(公告)日：2016-06-23
申请号：US15055156
申请日：2016-02-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Satoshi YAMAMOTO , Junya SHIRAI , Tsuneo ODA , Mitsunori KONO , Atsuko OCHIDA , Takashi IMADA , Hidekazu TOKUHARA , Yoshihide TOMATA , Naoki ISHII , Michiko TAWADA , Yoshiyuki FUKASE , Tomoya YUKAWA , Shoji FUKUMOTO
IPC: C07D471/04
CPC classification number: C07D217/26 , A61K31/4375 , A61K31/472 , A61K31/4741 , C07D217/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D491/14 , C07F7/0812
Abstract: The present invention provides a heterocyclic compound having a RORγt inhibitory action.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.028 seconds)
